RxDoctor Payments Data

Mark McGrath

Psychiatric/Mental Health · Missoula, MTNPI 1659870178

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations.

$681in general payments, 2019–2025

Across 31 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
  • Neurocrine Biosciences, Inc.$120
  • Johnson & Johnson$117
  • AbbVie$104
  • Teva Pharmaceuticals USA, Inc.$63
  • Indivior Inc.$37
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$681 in reported general payments places this provider in the 85th percentile of 142 psychiatric/mental health providers in Montana.

See all psychiatric/mental health providers in Montana

Medicare billing

Part B allowed, 2024
$45,838
Medicare patients
134
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$91,865
Invega SustennaPaliperidone Palmitate14$45,253
VraylarCariprazine Hcl24$24,905
Paliperidone ErPaliperidone16$6,789
Clozapine61$4,446
Lurasidone Hcl24$4,070
Duloxetine Hcl159$3,869
Lisdexamfetamine Dimesylate23$3,702
Divalproex Sodium ErDivalproex Sodium33$2,922
Quetiapine Fumarate210$2,771
Aripiprazole135$2,710
Venlafaxine Hcl ErVenlafaxine Hcl159$2,427
Desvenlafaxine Succinate ErDesvenlafaxine Succinate91$2,015
Bupropion XlBupropion Hcl112$1,870
Lamotrigine145$1,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$120$91,86511 claims
Johnson & JohnsonInvega Sustenna$117$45,25314 claims
AbbVieVraylar$104$24,90524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 142 psychiatric/mental health providers in Montana.

Other psychiatric/mental health in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →